Since their emergence as zoonotic pathogens in 1997, highly pathogenic avian influenza A (H5N1) viruses have spread across Asia, Europe, and Africa, posing a persisting threat to animal and human health globally \[[@CIT0001]\]. During 2017 and 2018 alone, outbreaks in poultry and wild birds were reported in 17 Asian and African countries, including 8 countries during the first 6 months of 2018, with millions of birds succumbing to the disease or culled to control outbreaks \[[@CIT0002]\].

Sporadic transmission to humans occurs during poultry outbreaks. Since 2003, 860 human H5N1 infections have been reported to the World Health Organization (WHO), with nearly two-thirds of cases occurring in Egypt and Indonesia. While the number of reported human infections has declined substantially in recent years despite continued circulation in birds, underreporting due to reduced awareness and limited diagnostic capacity in affected African and Asian countries cannot be excluded.

The overall mortality related to reported human infections is high (53%), with remarkable differences among countries and regions, ranging from 33% in Egypt to as high as 84% in Indonesia, where fewer than one-quarter of all reported cases but more than one-third of all deaths occurred \[[@CIT0003], [@CIT0004]\]. These regional differences in outcome might be related to differences in access to healthcare and clinical management among countries, differences in virulence of circulating viruses, or both. The relatively low mortality in Egypt compared to south and southeast Asian countries, where the case fatality rate is more than twice as high (69%), may, in part, be attributable to earlier identification, hospitalization, and antiviral treatment of patients in Egypt \[[@CIT0005]\]. However, the timing of hospitalization and treatment cannot readily explain the mortality differences among Asian countries. For example, despite similarly late treatment of patients in Vietnam and Indonesia (median, 6 days after illness onset), reported mortality in Vietnam is substantially lower (50% in Vietnam vs 84% in Indonesia) \[[@CIT0006], [@CIT0007]\]. Although genetically distinct H5N1 virus lineages circulate in different regions and countries, insights into possible differences in virulence or other viral characteristics that could impact clinical outcome are very limited. Studies that relate virological determinants to clinical outcome are largely limited to observations in small numbers of Vietnamese and Cambodian patients infected by clade 1 H5N1 viruses. These studies showed that a fatal outcome is associated with high pharyngeal viral loads, the presence of viremia, and a poor response to oseltamivir treatment due to antiviral resistance \[[@CIT0007][@CIT0013]\]. Comparable data from patients infected with other H5N1 virus clades may contribute to improved understanding of the differences in mortality but are currently lacking.

In the present study, we report detailed virological analyses in a range of clinical specimens from 180 Indonesian patients with laboratory-confirmed H5N1 infection, representing the first comprehensively studied series of human clade 2.1 H5N1 infections and the largest cohort of human H5N1 infections overall. In addition to confirming that high nasopharyngeal viral loads are associated with poor clinical outcome, the virus was more commonly detected in blood, and early antiviral responses to treatment with oseltamivir appeared less pronounced when compared to Vietnamese H5N1 clade 1--infected patients. Strikingly, the case fatality rate in Indonesia increased over time and was associated with increasing viral loads and the emergence of mutations in the matrix protein that confers adamantane resistance. These observations suggest that differences in virulence and other viral characteristics may contribute to the exceptionally high mortality related to human clade 2.1 H5N1 infections in Indonesia.

METHODS {#s1}
=======

Specimen and Data Collection {#s2}
----------------------------

The analyses were conducted on anonymized available specimens and associated demographic and clinical data from Indonesian patients with laboratory-confirmed H5N1 infection during the period 2005--2017. Specimens and data were collected and stored at the National Institute of Health Research and Development (NIHRD), Ministry of Health of Indonesia, as part of the national procedure for avian influenza case investigation. This national procedure prescribed to send clinical specimens to NIHRD in case of suspected H5N1 infection, including repeat respiratory specimens during hospitalization, for diagnostic and confirmatory testing \[[@CIT0014]\]. Specimens were stored at --80°C after laboratory confirmation was performed using H5-specific reverse-transcriptase polymerase chain reaction (RT-PCR) \[[@CIT0015]\]. The laboratory analyses of the current study were conducted on all available respiratory (nasal, pharyngeal, pleural, tracheal, bronchial), gastrointestinal (rectal, fecal), and blood specimens. Specimen and data collections were approved by the Ministry of Health of Indonesia as part of the national investigation of avian influenza \[[@CIT0014]\]. The current investigations were approved by the ethical and scientific review board of the NIHRD, Ministry of Health.

Virological Analyses {#s3}
--------------------

Viral RNA was isolated from clinical specimens using PureLink (Invitrogen/Thermo Fisher, Carlsbad, CA) or QIAamp (Qiagen, Hilde, Germany) RNA extraction kits, according to the manufacturers' instructions. Quantitative detection of H5N1 RNA was done batch-wise using real-time RT-PCR as described previously \[[@CIT0011], [@CIT0012]\]. The presence of mutations in the viral neuraminidase and matrix 2 (M2) genes that confer resistance to oseltamivir and adamantanes, respectively, was analyzed using pyrosequencing or Sanger sequencing \[[@CIT0016], [@CIT0017]\]. Viral RNA was reverse transcribed as described previously \[[@CIT0008], [@CIT0011], [@CIT0012]\] and amplified using gene-specific primers. Primer sequences are available upon request. Amplification was performed using Platinum Taq DNA Polymerase High Fidelity (Invitrogen, Carlsbad, CA) or HotStar Taq (Qiagen, Hilden, Germany) according to the manufacturers' instructions. The ExoSAP-IT (Affymetrix, Inc., Santa Clara, CA) purification kit was used to purify the PCR products. Pyrosequencing was performed on the PyroMark ID instrument using Pyro Gold Reagents kits (Biotage AB, Uppsala, Sweden). For Sanger sequencing, DNA was sequenced using the Big Dye Terminator v3.1 cycle sequencing kit (Applied Biosystems, Inc., Foster City, CA) according to the manufacturer's instructions using a 16-capillary 3130*xl* Genetic Analyzer (Applied Biosystems).

Statistical Analyses {#s4}
--------------------

The χ^2^ or Fisher exact test was used to compare categorical variables, and the Mann-Whitney test was used for group comparisons of continuous variables. Viral RNA loads were analyzed after log transformation. For statistical purposes, the lower detection limit of the assay (10 cDNA copies/mL) was used for correlation analyses in case no viral RNA could be detected. Correlations between variables were calculated using the Spearman rank correlation test. All statistical analyses were done using SPSS v14.0 (SPSS Inc., Chicago, IL) or Graphpad Prism 7.02 (GraphPad Software, La Jolla, CA). A *P* value \< .05 was considered statistically significant.

RESULTS {#s5}
=======

Patient Demographics and Outcome {#s6}
--------------------------------

Clinical specimens and associated demographic and clinical outcome data were available for analysis from 180 patients with laboratory-confirmed H5N1 infection, representing 90% of all Indonesian patients reported to WHO since the emergence of H5N1 influenza in Indonesia in 2005 until 2017 ([Figure 1A](#F1){ref-type="fig"}, [Table 1](#T1){ref-type="table"}). Patients originated from 15 of 34 Indonesian provinces, with the majority of cases from the province of Java ([Figure 1B](#F1){ref-type="fig"}). The median age of patients was 19 years (range, 1--67), and 54% were female ([Table 1](#T1){ref-type="table"}).

![Reported human H5N1 infections in Indonesia, 2005--2015. *A*, Number of human H5N1 infections in Indonesia reported to the World Health Organization (white bars) and cases included in this study (black bars). Lines depict case fatality proportions of reported infections (circles) and cases included in this study (squares). *B*, Geographical origin of cases. Size of pie diagrams reflect number of cases, with the dark fraction representing fatalities. Abbreviation: CFR, case fatality rate.](ciz328f0001){#F1}

###### 

Overview of Demographic and Clinical Characteristics of H5N1-Infected Patients

  ----------------------------------------- ---------------
  Median age (range), y                     19 (1--67)
  Gender                                    
  Female                                    97
  Male                                      83
  Year of infection                         
  2006                                      16
  2007                                      51
  2008                                      42
  2009                                      22
  2010                                      17
  2011                                      8
  2012                                      9
  2013                                      2
  2014                                      2
  2015                                      2
  Geographical origin                       
  Bali                                      6
  Banten                                    35
  Bengkulu                                  1
  Jakarta                                   45
  West Java                                 47
  Central Java                              10
  East Java                                 7
  Lampung                                   3
  West Nusa Tenggara                        1
  Riau                                      10
  South Sulawesi                            1
  West Sulawesi                             4
  South Sumatra                             1
  North Sumatra                             8
  Yogyakarta                                1
  Median days after symptom onset (range)   9 (--1 to 27)
  Antiviral treatment                       
  Yes                                       123
  No                                        57
  Clinical outcome                          
  Survival                                  27
  Death                                     153
  Type of specimen                          
  Upper respiratory tract                   699
  Nasal swabs                               346
  Pharyngeal swabs                          346
  Other                                     7
  Lower respiratory tract                   141
  Bronchial washes                          22
  Tracheal aspirates                        66
  Pleural fluids                            44
  Other                                     9
  Blood                                     26
  Gastrointestinal tract                    44
  Central nervous system                    1
  Other                                     3
  Total                                     914
  ----------------------------------------- ---------------

Of the 180 studied cases, 153 (85 %) were fatal. The case fatality rate increased from 73% in 2005 to 100% in 2012 and subsequent years ([Figure 1A](#F1){ref-type="fig"}). There were no significant differences in age, gender, or days since illness onset before presentation between surviving and fatal cases (data not shown). Over time, the days since illness onset were also similar each year until 2012 but appeared longer during the period 2013--2015, although numbers are very small ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}).

H5N1 RNA Load in Clinical Specimens {#s7}
-----------------------------------

Available stored clinical specimens from the 180 patients included nasal swabs from 164 (91%), pharyngeal swabs from 157 (88%), lower respiratory tract specimens (bronchial washes, tracheobronchial aspirates, pleural fluids) from 92 (52%), serum or plasma from 26 (14%), and rectal swabs or feces from 25 (14%). Quantitative detection of H5N1 RNA was performed in all 914 available specimens ([Table 1](#T1){ref-type="table"}).

Viral RNA was detected in 144 of 157 pharyngeal and 142 of 163 nasal specimens obtained at admission, with significantly higher H5N1 RNA levels observed in throat swabs than in nasal swabs ([Figure 2A](#F2){ref-type="fig"}). To estimate the natural course of viral RNA load during human H5N1 infection, viral loads in initial nasal and pharyngeal specimens obtained from individual patients prior to initiation of treatment were plotted against the days since reported onset of symptoms at the time of sample collection ([Supplementary Figure 2](#sup2){ref-type="supplementary-material"}). This showed that H5N1 RNA could be detected up to 19 days after onset of symptoms with no clear trend toward lower viral RNA levels in specimens collected later during the course of infection.

![Viral RNA load in clinical specimens. *A*, H5N1 RNA levels in admission NS and TS. *B*, Comparison of H5N1 RNA levels in NS and TS of F and S cases. H5N1 RNA levels in LRT, GIT, and blood specimens. Median value and interquartile range are depicted in red. Abbreviations: F, fatal; GIT, gastrointestinal tract; LRT, lower respiratory tract; NS, nasal swabs; S, surviving; TS, throat swabs. \**P* \< .05; \*\**P* \< .005.](ciz328f0002){#F2}

Both in nasal and pharyngeal specimens, H5N1 RNA levels were significantly higher in patients who died than in those who survived (nasal: median, 4.3 log vs 3.6 log cDNA copies/mL, respectively; *P* = .0135 and pharyngeal; mean, 5.3 log vs 4.5 log cDNA copies/mL, respectively; *P* = .041; [Figure 2B](#F2){ref-type="fig"}). During the study period, median viral RNA loads in pretreatment specimens gradually increased, which correlated significantly with the rising mortality rates during the same period (Spearman ρ = .86, *P* = .0014; [Figure 3](#F3){ref-type="fig"}).

![Viral RNA load and prevalence of amantadine resistance over time. *A*, H5N1 RNA levels in admission throat swabs per year of infection. Median value indicated in red. *B*, Prevalence of amantadine resistance-conferring M2 mutations over time.](ciz328f0003){#F3}

Viral RNA was also detected in 85 of 92 lower respiratory tract specimens, of which all except 4 were collected from fatal cases ([Figure 2C](#F2){ref-type="fig"}). In 20 of 25 (80%) patients, viral RNA could be detected in rectal swabs or feces. Detection rates and viral loads were similar between fatal and surviving cases, but the number of surviving cases from whom specimens were available was small (n = 4). In available serum or blood specimens, viral RNA was detected in 22 of 26 (85%) patients, with similar detection rates observed in fatal and surviving cases (14 of 16 \[88%\] and 8 of 10 \[80%\] patients, respectively). Viral RNA levels in blood were higher in fatal cases, but this difference did not reach statistical significance (median, 3.7 log cDNA copies/mL \[range, 2.9--4.4\] vs 3.2 \[range 2.5--3.9\], respectively; *P* = .08).

Response to Antiviral Treatment {#s8}
-------------------------------

Treatment with oseltamivir had a statistically significant impact on clinical outcome: 22 of 123 patients (18%) who received treatment survived vs none of the remaining 57 untreated patients (*P* \< .001). The median duration from onset of illness to initiation of treatment was 7 days (range, 0--18), with no statistically significant differences between surviving and fatal cases (median, 6 days \[range 0--18\] vs 7 days \[range 0--14\], respectively; *P* = .15). However, the survival rate was significantly higher in patients treated earlier than the median of 7 days compared to those treated on day 7 or later (16/51 \[31%\] vs 11/71 \[15%\], respectively; *P* = .037). This difference in survival was more pronounced when patients treated on or before 4 days after illness onset were compared to those treated later (8/16 \[50%\] vs 19/106 \[18%\], respectively; *P* = .004).

Serial pharyngeal specimens collected before and during antiviral treatment were available from 34 patients. The median reduction in viral RNA load after 2 days of treatment was 0.55 log cDNA copies/mL (range, --4.5 to 1.5), with only 2 patients reaching undetectable levels within 2 days ([Figure 4](#F4){ref-type="fig"}). During subsequent days, viral RNA remained detectable in 6 of 6 patients at day 3 and in 2 of 3 patients at days 4 and 5.

![Viral RNA load during oseltamivir treatment. *A*, H5N1 RNA levels in serial throat swabs collected from fatal (black line) and surviving (dashed line) cases before and during oseltamivir treatment. *B*, Changes in H5N1 RNA load from pretreatment baseline levels. Median value and interquartile range are depicted in red.](ciz328f0004){#F4}

Oseltamivir and Adamantane Resistance Mutations {#s9}
-----------------------------------------------

The presence of the oseltamivir resistance--conferring His275Tyr (H275Y) substitution in neuraminidase (NA) was investigated in admission respiratory specimens from 155 patients and in 168 pharyngeal samples collected from 78 patients after initiation of oseltamivir treatment ([Supplementary Table 1](#sup3){ref-type="supplementary-material"}) and was not observed in any of the specimens tested.

While detection of the H275Y substitution was based on residue-specific pyrosequencing methods in the majority of specimens, Sanger sequencing was used in a proportion of samples, which allowed detection of 2 other resistance-conferring substitutions, that is, R293K and N295S (N1 numbering) \[[@CIT0018]\]. Neither of these substitutions was found in 29 specimens from 14 patients after initiation of treatment ([Supplementary Table 2](#sup3){ref-type="supplementary-material"}) and in specimens from 14 patients with no treatment.

Sequence analyses of the M2 gene in admission specimens from 153 patients revealed the presence of mutations that confer resistance to adamantanes in 131 (85.6%) patients. The mutations identified were Val27Ala (n = 109), Val27Thr (n = 1), Ser31Asn (n = 7), Val27Ala + Ser31Asn (n = 3), Val27Ala + Ser31Gly (n = 7), and Leu26Ile + Ser31Asn (n = 4). M2 resistance mutations were detected more frequently in fatal cases compared to survivors (117/132 \[89%\] vs 14/21 \[67%\], respectively; *P* = .015). Over time, the prevalence of M2 resistance mutations increased gradually from 37.5% in 2005 to 95% in 2009 and to 100% during subsequent years ([Figure 3B](#F3){ref-type="fig"}). These increases correlated with increasing median pharyngeal viral RNA loads during the same period (Spearman ρ = 0.83; *P* = .0019). As a result, admission viral RNA loads in throat specimens from patients who harbored virus with M2 resistance mutations were higher than those from patients infected with virus without these mutations (median, 5.3 log cDNA copies/mL vs 4.3 log cDNA copies/mL; *P* = .0042).

DISCUSSION {#s10}
==========

In a large cohort of 180 Indonesian patients with influenza A/H5N1 infection, representing one-fifth of all globally reported cases and 90% of those reported from Indonesia, we provide information to explain the exceptionally high and increasing mortality related to human H5N1 clade 2.1 infections in Indonesia.

As shown previously in small case series of patients infected with clade 1 H5N1 viruses, viral RNA could be detected in respiratory specimens at high levels for more than 2 weeks after illness onset, indicating prolonged virus replication and shedding during the course of the disease \[[@CIT0007][@CIT0013]\]. Furthermore, a fatal outcome was not only associated with higher viral loads in the throat, as has been reported previously, but also in nasal specimens. The limited number of patients investigated in previous series may explain why the latter was not observed before. The detection rates of viral RNA in gastrointestinal specimens and particularly in blood were higher in Indonesian patients than previously reported in Vietnamese H5N1-infected patients (gastrointestinal, 80% vs 71% and blood, 85% vs 56%, respectively) \[[@CIT0008]\]. It remains unclear whether the detection of viral RNA in these specimens reflects infectious virus since no attempts were made to isolate virus due to sample volume restrictions. However, isolation of infectious virus from feces and blood during human H5N1 infections has previously been reported \[[@CIT0012], [@CIT0019]\]. Hence, although numbers of patients in this and previous series were small, it is tempting to speculate that higher rates of viremia in our patients and consequent increased risk of systemic spread of clade 2.1 viruses may have contributed to the higher mortality among Indonesian patients.

Treatment with oseltamivir was associated with a survival benefit. This benefit was greater when treatment was started earlier in the course of infection, confirming earlier observations and emphasizing the need for early recognition and diagnosis \[[@CIT0007], [@CIT0020]\]. Although differences in survival among countries may be difficult to interpret in view of possible differences in healthcare access and medical practices among H5N1-affected regions, reported survival in oseltamivir-treated patients infected by clade 1 H5N1 viruses is substantially higher than in our clade 2.1-infected patients (52.5% vs 18%), despite late treatment initiation in both \[[@CIT0021]\]. Common oseltamivir resistance--conferring neuraminidase mutations, including H275Y, R293K, and N295S \[[@CIT0018]\], were not detected during treatment in any of the specimens tested. In addition, we looked for a range of other neuraminidase mutations reportedly associated with reduced oseltamivir susceptibility in recently published whole-genome, next-generation sequencing data that we generated from 44 Indonesian patients to study viral quasispecies evolution during human infection ([Supplementary Table 3](#sup3){ref-type="supplementary-material"}) \[[@CIT0022]\]. Except for 2 variants present as minority viral populations in 4 patients (V116A in 3 patients at 3.6%--6.0% of the viral population, N295S in 1 at 1.6%), other substitutions were not observed \[[@CIT0023][@CIT0026]\].

The above observations argue against the emergence of known resistance mutations to explain the apparent limited benefit of oseltamivir treatment in Indonesian patients. However, in vitro susceptibility testing of H5N1 viruses has shown that clade 2.1 viruses are intrinsically up to 30-fold less susceptible to oseltamivir than clade 1 viruses \[[@CIT0027]\]. Similar differences in oseltamivir susceptibility between human seasonal influenza A and B viruses have been linked to a longer duration of virus shedding and fever during treatment of influenza B virus--infected patients \[[@CIT0028], [@CIT0029]\]. Along the same lines, it cannot be excluded that similar differences in drug susceptibility between clade 1 and clade 2.1 H5N1 viruses are associated with differences in antiviral responses and consequently clinical benefit. In a small case series of Vietnamese H5N1 clade 1--infected patients, rapid reductions in viral RNA to undetectable levels, mostly within 2 days of treatment, were observed in surviving patients, while viral RNA remained detectable at high levels in fatal cases and was associated with the emergence of resistance \[[@CIT0011]\]. These observations appear to contrast with our findings in Indonesian patients that show that, despite an absence of oseltamivir resistance mutations, viral RNA was still detectable after 2 days of treatment in 42 of 44 patients and remained detectable throughout the course of treatment in the vast majority of patients who were followed. Although the numbers of evaluated patients are limited, this might be explained by the aforementioned differences in oseltamivir susceptibility.

Changes in mortality were observed during the study period, increasing from 69% overall to 100% in 2012 and beyond. These changes in mortality over time correlated with increasing admission viral loads and with an increasing prevalence of viruses that contain adamantane resistance--conferring M2 mutations during the same period. In turn, admission viral loads were higher in the presence of M2 mutations.

Time from illness onset to presentation of patients and initiation of treatment remained similar until 2012 but appeared longer thereafter, which may have contributed to the high mortality during that period. However, the increasing viral loads during the same period remain striking given that no correlation between viral RNA load and illness duration was observed overall ([Supplementary Figure 2](#sup2){ref-type="supplementary-material"}). In addition to supporting an important role of viral load in determining outcome, these observations suggest an increasing virulence of circulating H5N1 viruses over time, possibly associated with the presence of M2 substitutions. Similar to observations in seasonal human influenza viruses \[[@CIT0030], [@CIT0031]\], the increasing prevalence of adamantane resistance M2 mutations in Indonesian H5N1 viruses occurred in the absence of apparent widespread use of amantadine, neither in poultry nor in humans. This suggests that the presence of these mutations is associated with a natural fitness advantage, either indirectly through a genetic "hitchhiking" effect in association with changes elsewhere in the viral genome or directly through potential advantageous effects on the biological function of the M2 protein. The latter direct biological role of observed M2 mutations in enhancing virulence cannot be excluded and deserves further study. In murine experiments, mortality in mice infected with isogenic recombinant H1N1 viruses that harbored amantadine resistance mutations (Val27Ala, Ser31Gly, or both) was higher than in mice infected with wild-type H1N1 viruses \[[@CIT0032], [@CIT0033]\]. Furthermore, the Val27Ala change in M2, representing the most prevalent mutation observed in our patients, has been associated with increased M2 activity in avian influenza A/H7N1 viruses, which suggests that this particular substitution may have functional significance \[[@CIT0034]\].

In summary, our study of a large series of H5N1-infected Indonesian patients confirms the association between high upper respiratory viral loads and fatal outcome and provides information to explain the exceptionally high mortality related to H5N1 disease in Indonesia, including a high proportion of patients with viremia, potential suboptimal antiviral efficacy of oseltamivir, and an increasing virulence of circulating viruses, possibly associated with the emergence of M2 mutations. These observations deserve consideration in future further research efforts in human infections with H5N1 and other avian influenza viruses.

Supplementary Data {#s11}
==================

Supplementary materials are available at *Clinical Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.
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